TN2010000212A1 - Inhibitors of human immunodeficiency virus replication - Google Patents

Inhibitors of human immunodeficiency virus replication

Info

Publication number: TN2010000212A1
Authority: TN; Tunisia
Prior art keywords: inhibitors; immunodeficiency virus; human immunodeficiency; virus replication; replication
Prior art date: 2007-11-16

Application number

TN2010000212A

Other languages

English (en)

Original Assignee

Gilead Sciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-11-16

Filing date

2010-05-14

Publication date

2011-11-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40638275&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2010000212(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-05-14 Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc

2011-11-11 Publication of TN2010000212A1 publication Critical patent/TN2010000212A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Engineering & Computer Science (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
AIDS & HIV (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Quinoline Compounds (AREA)

TN2010000212A 2007-11-16 2010-05-14 Inhibitors of human immunodeficiency virus replication TN2010000212A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US98868607P	2007-11-16	2007-11-16
PCT/CA2008/001611 WO2009062285A1 (fr)	2007-11-16	2008-09-11	Inhibiteurs de la réplication du virus de l'immunodéficience humaine

Publications (1)

Publication Number	Publication Date
TN2010000212A1 true TN2010000212A1 (en)	2011-11-11

Family

ID=40638275

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TN2010000212A TN2010000212A1 (en)	2007-11-16	2010-05-14	Inhibitors of human immunodeficiency virus replication

Country Status (26)

Country	Link
US (3)	US8354429B2 (fr)
EP (2)	EP2757096A1 (fr)
JP (2)	JP5285709B2 (fr)
KR (1)	KR20100097156A (fr)
CN (1)	CN101918365B (fr)
AR (1)	AR069335A1 (fr)
AU (1)	AU2008323558C1 (fr)
BR (1)	BRPI0820307A2 (fr)
CA (1)	CA2707418C (fr)
CL (1)	CL2008003406A1 (fr)
CO (1)	CO6280400A2 (fr)
EA (2)	EA201200631A1 (fr)
EC (1)	ECSP10010206A (fr)
HK (1)	HK1199731A1 (fr)
IL (1)	IL205581A (fr)
MA (1)	MA31906B1 (fr)
MX (1)	MX2010005334A (fr)
NZ (1)	NZ585226A (fr)
PE (3)	PE20091000A1 (fr)
SG (1)	SG185995A1 (fr)
TN (1)	TN2010000212A1 (fr)
TW (1)	TWI437992B (fr)
UA (1)	UA100250C2 (fr)
UY (1)	UY31472A1 (fr)
WO (1)	WO2009062285A1 (fr)
ZA (1)	ZA201003283B (fr)

Families Citing this family (196)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5269086B2 (ja) *	2007-11-15	2013-08-21	ギリアードサイエンシスインコーポレーテッド	ヒト免疫不全ウイルスの複製阻害薬
EA201200631A1 (ru) *	2007-11-16	2012-11-30	Джилид Сайенсиз, Инк.	Ингибиторы репликации вируса иммунодефицита человека
WO2010077613A1 (fr)	2008-12-09	2010-07-08	Gilead Sciences, Inc.	Modulateurs de récepteurs de type toll (tlr)
GB0908394D0 (en)	2009-05-15	2009-06-24	Univ Leuven Kath	Novel viral replication inhibitors
US8338441B2 (en)	2009-05-15	2012-12-25	Gilead Sciences, Inc.	Inhibitors of human immunodeficiency virus replication
GB0913636D0 (en)	2009-08-05	2009-09-16	Univ Leuven Kath	Novel viral replication inhibitors
PH12013500015A1 (en)	2010-07-02	2013-02-18	Gilead Sciences Inc	2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds
US9102614B2 (en) *	2010-07-02	2015-08-11	Gilead Sciences, Inc.	Naphth-2-ylacetic acid derivatives to treat AIDS
US8633200B2 (en)	2010-09-08	2014-01-21	Bristol-Myers Squibb Company	Inhibitors of human immunodeficiency virus replication
US9132129B2 (en)	2010-11-15	2015-09-15	Katholieke Universiteit Leuven	Antiviral compounds
CA2830838A1 (fr)	2011-04-04	2012-11-10	Gilead Sciences, Inc.	Procede de preparation d'un inhibiteur de l'integrase du vih
JP2014510139A (ja) *	2011-04-04	2014-04-24	ギリアードサイエンシーズ，インコーポレイテッド	固体形態のｈｉｖ阻害剤
EP2508511A1 (fr)	2011-04-07	2012-10-10	Laboratoire Biodim	Inhibiteurs de la réplication virale, leur procédé de préparation et leurs utilisations thérapeutiques
ES2742261T3 (es) *	2011-04-15	2020-02-13	Hivih	Inhibidores de la replicación viral, su proceso de preparación y sus usos terapéuticos
EA024952B1 (ru)	2011-04-21	2016-11-30	Джилид Сайэнс, Инк.	Бензотиазолы и их применение для лечения вич-инфекции
CA2840095A1 (fr)	2011-07-06	2013-01-10	Gilead Sciences, Inc.	Composes pour traiter le vih
US8609653B2 (en)	2011-07-15	2013-12-17	Glaxosmithkline Llc	Azaindole compounds and methods for treating HIV
US8791108B2 (en)	2011-08-18	2014-07-29	Bristol-Myers Squibb Company	Inhibitors of human immunodeficiency virus replication
WO2013043553A1 (fr) *	2011-09-22	2013-03-28	Glaxosmithkline Llc	Composés pyrrolopyridinones et méthodes de traitement du vih
JP6099149B2 (ja)	2011-10-25	2017-03-22	塩野義製薬株式会社	Ｈｉｖ複製阻害剤
WO2013073875A1 (fr)	2011-11-15	2013-05-23	한국화학연구원	Dérivé antiviral inédit de pyrrolopyridine et son procédé de production
US9284323B2 (en)	2012-01-04	2016-03-15	Gilead Sciences, Inc.	Naphthalene acetic acid derivatives against HIV infection
US9376392B2 (en)	2012-01-04	2016-06-28	Gilead Sciences, Inc.	2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
US8629276B2 (en)	2012-02-15	2014-01-14	Bristol-Myers Squibb Company	Inhibitors of human immunodeficiency virus replication
US9034882B2 (en) *	2012-03-05	2015-05-19	Bristol-Myers Squibb Company	Inhibitors of human immunodeficiency virus replication
US9006235B2 (en)	2012-03-06	2015-04-14	Bristol-Myers Squibb Company	Inhibitors of human immunodeficiency virus replication
RU2014115227A (ru)	2012-04-20	2015-10-27	Джилид Сайэнс, Инк.	Производные бензотиазол-6-ил уксусной кислоты и их примение для лечения вич-инфекции
KR20150021510A (ko) *	2012-05-03	2015-03-02	시플라 리미티드	항레트로바이러스 조성물
EP2877468B1 (fr) *	2012-07-12	2017-08-23	ViiV Healthcare UK Limited	Composés et procédés de traitement du vih
US8906929B2 (en)	2012-08-16	2014-12-09	Bristol-Myers Squibb Company	Inhibitors of human immunodeficiency virus replication
WO2014055618A1 (fr)	2012-10-03	2014-04-10	Gilead Sciences, Inc.	Formes à l'état solide d'inhibiteur du vih : hémisuccinate d'acide (2s)-2-tert-butoxy-2-(4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)-2-méthylquinolin-3-yl)acétique
WO2014055603A1 (fr) *	2012-10-03	2014-04-10	Gilead Sciences, Inc.	Procédé de préparation d'un inhibiteur d'intégrase du vih
EP2716639A1 (fr)	2012-10-05	2014-04-09	Laboratoire Biodim	Inhibiteurs de la réplication virale, leur procédé de préparation et leurs utilisations thérapeutiques
EP2716632A1 (fr)	2012-10-05	2014-04-09	Laboratoire Biodim	Inhibiteurs de la réplication virale, leur procédé de préparation et leurs utilisations thérapeutiques
EP2719685A1 (fr)	2012-10-11	2014-04-16	Laboratoire Biodim	Inhibiteurs de la réplication virale, leur procédé de préparation et leurs utilisations thérapeutiques
PH12019501848A1 (en)	2012-12-21	2020-03-02	Gilead Sciences Inc	Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US9012441B2 (en)	2013-01-09	2015-04-21	Gilead Sciences, Inc.	Therapeutic compounds
TW201443037A (zh)	2013-01-09	2014-11-16	Gilead Sciences Inc	治療用化合物
NZ631762A (en)	2013-01-09	2017-02-24	Gilead Sciences Inc	5-membered heteroaryls and their use as antiviral agents
TW201441197A (zh)	2013-01-31	2014-11-01	Shionogi & Co	Ｈｉｖ複製抑制劑
TWI694071B (zh)	2013-03-01	2020-05-21	美商基利科學股份有限公司	治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
CN105189510B (zh)	2013-03-13	2017-05-17	百时美施贵宝公司	人免疫缺陷病毒复制的抑制剂
JP2016512511A (ja)	2013-03-13	2016-04-28	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	ヒト免疫不全ウイルス複製の阻害剤
CN105008358B (zh)	2013-03-13	2017-12-29	百时美施贵宝公司	人免疫缺陷病毒复制的抑制剂
ES2623904T3 (es)	2013-03-14	2017-07-12	VIIV Healthcare UK (No.5) Limited	Inhibidores de la replicación del virus de la inmunodeficiencia humana
US9540393B2 (en)	2013-03-14	2017-01-10	VIIV Healthcare UK (No.5) Limited	Inhibitors of human immunodeficiency virus replication
CA2914132A1 (fr)	2013-06-21	2014-12-24	Lupin Limited	Composes heterocycliques substitues utiles en tant que modulateurs de crac
AU2014300629A1 (en)	2013-06-24	2015-12-24	Lupin Limited	Chromane and chromene derivatives and their use as CRAC modulators
EP2821082A1 (fr)	2013-07-05	2015-01-07	Laboratoire Biodim	Procédé de production d'un lentivirus inactivé, notamment le VIH, vaccin, kit et procédé d'utilisation
EP2821104A1 (fr)	2013-07-05	2015-01-07	Laboratoire Biodim	Inhibiteurs de la réplication virale, leur procédé de préparation et leurs utilisations thérapeutiques
WO2015006731A1 (fr)	2013-07-12	2015-01-15	Gilead Sciences, Inc.	Composés de carbamoylpyridone polycyclique et leur utilisation pour le traitement des infections à vih
NO2865735T3 (fr)	2013-07-12	2018-07-21
CN103467374A (zh) *	2013-08-30	2013-12-25	江苏弘和药物研发有限公司	一种8-溴-4-羧基喹啉的合成方法
EP3105236B1 (fr)	2014-02-12	2017-10-18	ViiV Healthcare UK (No.5) Limited	Utilisation de macrocycles de benzothiazole comme qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine
EP3152215A1 (fr)	2014-02-18	2017-04-12	ViiV Healthcare UK (No.5) Limited	Macrocycles de pyrazolopyrimidine utilisés en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine
US9409922B2 (en)	2014-02-18	2016-08-09	Bristol-Myers Squibb Company	Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication
US9932353B2 (en)	2014-02-18	2018-04-03	Viiv Healthcare Uk (No. 5) Limited	Imidazopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
WO2015126765A1 (fr)	2014-02-19	2015-08-27	Bristol-Myers Squibb Company	Inhibiteurs de la réplication du virus de l'immunodéficience humaine
US9273067B2 (en)	2014-02-19	2016-03-01	Bristol-Myers Squibb Company	Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
US9193720B2 (en)	2014-02-20	2015-11-24	Bristol-Myers Squibb Company	Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
EP3116880B1 (fr)	2014-02-20	2018-03-21	VIIV Healthcare UK (No.5) Limited	Macrocycles pyridin-3-yl-acide acétique en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine
US10202353B2 (en)	2014-02-28	2019-02-12	Gilead Sciences, Inc.	Therapeutic compounds
US9975906B2 (en)	2014-05-16	2018-05-22	Shionogi & Co., Ltd.	Tricyclic heterocycle derivatives having HIV replication inhibitory effect
WO2015179448A1 (fr) *	2014-05-21	2015-11-26	Gilead Sciences, Inc.	Composés thérapeutiques
NO2717902T3 (fr)	2014-06-20	2018-06-23
TW201613936A (en)	2014-06-20	2016-04-16	Gilead Sciences Inc	Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
WO2016007765A1 (fr)	2014-07-11	2016-01-14	Gilead Sciences, Inc.	Modulateurs de récepteurs de type toll pour le traitement du vih
US10118894B2 (en)	2014-07-22	2018-11-06	Viiv Healthcare Uk Limited	Isoindolinone derivatives useful as antiviral agents
US20160067255A1 (en)	2014-09-04	2016-03-10	Gilead Sciences, Inc.	Methods of treating or preventing hiv in patients using a combination of tenofovir alafenamide and dolutegravir
CA2960436C (fr)	2014-09-16	2021-01-05	Gilead Sciences, Inc.	Formes solides d'un modulateur de recepteurs de type toll
TWI695003B (zh)	2014-12-23	2020-06-01	美商基利科學股份有限公司	多環胺甲醯基吡啶酮化合物及其醫藥用途
TWI699355B (zh)	2014-12-24	2020-07-21	美商基利科學股份有限公司	喹唑啉化合物
MX2017008520A (es)	2014-12-24	2018-03-01	Gilead Sciences Inc	Compuestos de pirimidina fusionada para el tratamiento del virus de inmunodeficiencia humana (vih).
BR112017013440A2 (pt)	2014-12-24	2018-01-09	Gilead Sciences, Inc.	compostos de isoquinolina para o tratamento de hiv
HUE038059T2 (hu)	2015-03-04	2018-10-29	Gilead Sciences Inc	Toll-like receptor moduláló 4,6-diamino-pirido[3,2-D]pirimidin vegyületek
BR112017020837A2 (pt)	2015-04-02	2018-07-03	Gilead Sciences, Inc.	compostos de carbamoilpiridona policíclicos e seu uso farmacêutico
HK1253539A1 (en)	2015-05-29	2019-06-21	Shionogi & Co., Ltd.	Nitrogen-containing tricyclic derivative having hiv replication inhibitory activity
AU2016290152A1 (en)	2015-07-06	2018-01-18	VIIV Healthcare UK (No.5) Limited	Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
EP3319957A1 (fr)	2015-07-08	2018-05-16	VIIV Healthcare UK (No.5) Limited	Dérivés de l'acide pyridin-3-yl-acétique utilisés comme inhibiteurs de la réplication du virus de l'immunodéficience humaine
RU2018103032A (ru)	2015-07-09	2019-08-09	ВАЙВ ХЕЛТКЕР ЮКей (N5) ЛИМИТЕД	Производные пиридин-3-ил-уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека
CA2991464A1 (fr)	2015-07-09	2017-01-12	VIIV Healthcare UK (No.5) Limited	Derives de l'acide pyridin-3-yl-acetique utilises comme inhibiteurs de la replication du virus de l'immunodeficience humaine
US10709697B2 (en)	2015-07-16	2020-07-14	Emory University	Bis-amines, compositions, and uses related to CXCR4 inhibition
CA2994512A1 (fr)	2015-08-07	2017-02-16	VIIV Healthcare UK (No.5) Limited	Derives d'acide pyridin-3-yl acetique comme inhibiteurs de la replication du virus de l'immunodeficience humaine
CA2994517A1 (fr)	2015-08-10	2017-02-16	VIIV Healthcare UK (No.5) Limited	Macrocycles d'imidazopyridine en tant qu'inhibiteurs de la replication du virus de l'immunodeficience humaine
TWI657086B (zh)	2015-08-11	2019-04-21	英商Viiv醫療保健英國(No.5)有限公司	做為人類免疫缺陷病毒複製抑制劑之５－（ｎ－苯甲基四氫異喹啉－６－基）吡啶－３－基乙酸衍生物
AU2016305339A1 (en)	2015-08-12	2018-03-01	VIIV Healthcare UK (No.5) Limited	5-(n-fused tricyclic Aryl tetrahydroisoquinolin-6-yl) pyridin-3- yl acetic acid derivatives as inhibitors of Human Immunodeficiency Virus replication
TW201718537A (zh)	2015-08-12	2017-06-01	Ｖｉｉｖ醫療保健英國（Ｎｏ．５）有限公司	做為人類免疫缺陷病毒複製抑制劑之吡啶－３－基乙酸衍生物
PT3334723T (pt)	2015-08-12	2019-12-19	Viiv Healthcare Uk No 5 Ltd	Composto, composição, e, método para tratar infecção por hiv
CN108368093A (zh)	2015-08-20	2018-08-03	Viiv保健英国第五有限公司	作为人免疫缺陷病毒复制的抑制剂的吡啶-3-基乙酸衍生物
JP2018525412A (ja)	2015-08-26	2018-09-06	ギリアードサイエンシーズ，インコーポレイテッド	重水素化トール様受容体調節因子
MA42818A (fr)	2015-09-15	2018-07-25	Gilead Sciences Inc	Modulateurs de récepteurs de type toll pour le traitement du vih
US10059697B2 (en)	2015-09-30	2018-08-28	Gilead Sciences, Inc.	Compounds and combinations for the treatment of HIV
CN114848812B (zh)	2015-12-15	2025-01-10	吉利德科学公司	人免疫缺陷病毒中和抗体
US20190152957A1 (en)	2016-05-11	2019-05-23	VIIV Healthcare UK (No.5) Limited	Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
WO2017195113A1 (fr)	2016-05-11	2017-11-16	VIIV Healthcare UK (No.5) Limited	Dérivés d'acide pyridin-3-yle acétique utilisés comme inhibiteurs de la réplication du virus de l'immunodéficience humaine
JP2019515000A (ja)	2016-05-11	2019-06-06	ヴィーブヘルスケアユーケー（ナンバー５）リミテッド	ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
JP6998937B2 (ja) *	2016-08-12	2022-01-18	バイエル・クロップサイエンス・アクチェンゲゼルシャフト	２－（２－ジアゾニウム－６－置換フェニル）エタノール塩を環化させることによる４－置換２，３－ジヒドロ－１－ベンゾフラン誘導体の製造方法
HUE063811T2 (hu)	2016-08-19	2024-02-28	Gilead Sciences Inc	HIV-vírus-fertõzés megelõzõ vagy terápiás kezelésére alkalmas terápiás vegyületek
WO2018042332A1 (fr)	2016-08-31	2018-03-08	Glaxosmithkline Intellectual Property (No.2) Limited	Combinaisons, utilisations et traitements correspondants
WO2018042331A1 (fr)	2016-08-31	2018-03-08	Glaxosmithkline Intellectual Property (No.2) Limited	Combinaisons, utilisations et traitements correspondants
ES2826748T3 (es)	2016-09-02	2021-05-19	Gilead Sciences Inc	Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll
US10370342B2 (en)	2016-09-02	2019-08-06	Gilead Sciences, Inc.	Toll like receptor modulator compounds
WO2018051250A1 (fr)	2016-09-14	2018-03-22	Viiv Healthcare Company	Combinaison comprenant du ténofovir alafénamide, du bictégravir et du 3tc
ES2992772T3 (en)	2016-09-28	2024-12-18	Gilead Sciences Inc	Benzothiazol-6-yl acetic acid derivatives and their use for treating hiv infection
ES2881949T3 (es)	2016-10-27	2021-11-30	Gilead Sciences Inc	Forma cristalina de base libre de darunavir
TW201835068A (zh)	2017-01-03	2018-10-01	英商Viiv醫療保健英國(No.5)有限公司	作為人類免疫缺乏病毒複製之抑制劑之吡啶-3-基乙酸衍生物
US20200016136A1 (en)	2017-01-03	2020-01-16	Viiv Healthcare Uk (No. 5) Limited	Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
WO2018138050A1 (fr)	2017-01-26	2018-08-02	Bayer Aktiengesellschaft	Dérivés hétérocycliques bicycliques condensés utilisés comme pesticides
TWI714820B (zh)	2017-01-31	2021-01-01	美商基利科學股份有限公司	替諾福韋艾拉酚胺(tenofovir alafenamide)之晶型
JOP20180009A1 (ar)	2017-02-06	2019-01-30	Gilead Sciences Inc	مركبات مثبط فيروس hiv
CA3057586C (fr) *	2017-03-24	2022-05-03	St Pharm Co., Ltd.	Compose de pyrrolopyridine, methode de preparation et utilisationon
EP3642229A1 (fr)	2017-06-21	2020-04-29	Gilead Sciences, Inc.	Anticorps multispécifiques ciblant gp120 et cd3 du vih
JP7287906B2 (ja)	2017-06-30	2023-06-06	ヴィーブヘルスケアカンパニー	組み合わせ並びにその使用及びそれによる治療
ES2892402T3 (es)	2017-08-01	2022-02-04	Gilead Sciences Inc	Formas cristalinas de ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2-il)oxi)metil)(fenoxi)fosforil)-L-alaninato de etilo para tratar infecciones virales
AR112413A1 (es)	2017-08-17	2019-10-23	Gilead Sciences Inc	Formas sólidas de un inhibidor de la cápside del vih
AR112412A1 (es)	2017-08-17	2019-10-23	Gilead Sciences Inc	Formas de sal de colina de un inhibidor de la cápside del vih
EP3672970A1 (fr)	2017-08-22	2020-07-01	Gilead Sciences, Inc.	Composés hétérocycliques thérapeutiques
JOP20180092A1 (ar)	2017-10-13	2019-04-13	Gilead Sciences Inc	مثبطات hiv بروتياز
US20190151307A1 (en)	2017-10-24	2019-05-23	Gilead Sciences, Inc.	Methods of treating patients co-infected with a virus and tuberculosis
CA3084582A1 (fr)	2017-12-20	2019-06-27	Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.	Dinucleotides 2'3' cycliques ayant une liaison phosphonate activant la proteine adaptatrice de sting
CN111566120B (zh)	2017-12-20	2023-09-29	捷克共和国有机化学与生物化学研究所	活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸
WO2019144015A1 (fr)	2018-01-19	2019-07-25	Gilead Sciences, Inc.	Métabolites du bictégravir
WO2019161017A1 (fr)	2018-02-15	2019-08-22	Gilead Sciences, Inc.	Dérivés de pyridine et leur utilisation pour le traitement d'une infection par le vih
CA3175384A1 (fr)	2018-02-16	2019-08-22	Gilead Sciences, Inc.	Methodes et intermediaires pour preparer des composes therapeutiques utiles dans le traitement d'une infection virale des retroviridae
TWI818007B (zh)	2018-04-06	2023-10-11	捷克科學院有機化學與生物化學研究所	2'3'-環二核苷酸
TWI833744B (zh)	2018-04-06	2024-03-01	捷克科學院有機化學與生物化學研究所	3'3'-環二核苷酸
TW202005654A (zh)	2018-04-06	2020-02-01	捷克科學院有機化學與生物化學研究所	２，２，─環二核苷酸
WO2019211799A1 (fr)	2018-05-03	2019-11-07	Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.	Analogue de dinucléotide 2'3'-cyclique comprenant un nucléotide modifié par cyclopentanyle
WO2019244066A2 (fr)	2018-06-19	2019-12-26	VIIV Healthcare UK (No.5) Limited	Dérivés d'acide pyridin-3-yl-acétique en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine
WO2020003093A1 (fr)	2018-06-25	2020-01-02	VIIV Healthcare UK (No.5) Limited	Dérivés d'acide pyridin-3-yl-acétique en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine
SG11202012043RA (en)	2018-07-03	2021-01-28	Gilead Sciences Inc	Antibodies that target hiv gp120 and methods of use
AU2019297428C1 (en)	2018-07-06	2023-03-23	Gilead Sciences, Inc.	Therapeutic heterocyclic compounds
US11098027B2 (en)	2018-07-06	2021-08-24	Gilead Sciences, Inc.	Therapeutic heterocyclic compounds
TWI814350B (zh)	2018-07-16	2023-09-01	美商基利科學股份有限公司	用於治療hiv之蛋白殼抑制劑
TWI766172B (zh)	2018-07-30	2022-06-01	美商基利科學股份有限公司	抗hiv化合物
CA3113011A1 (fr)	2018-09-19	2020-03-26	Gilead Sciences, Inc.	Inhibiteurs d'integrase pour la prevention du vih
WO2020072656A1 (fr)	2018-10-03	2020-04-09	Gilead Sciences, Inc.	Dérivés d'imidozopyrimidine
PE20211655A1 (es)	2018-10-31	2021-08-24	Gilead Sciences Inc	Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1
TWI721624B (zh)	2018-10-31	2021-03-11	美商基利科學股份有限公司	經取代之6-氮雜苯并咪唑化合物
WO2020176505A1 (fr)	2019-02-25	2020-09-03	Gilead Sciences, Inc.	Agonistes de protéine kinase c
WO2020176510A1 (fr)	2019-02-25	2020-09-03	Gilead Sciences, Inc.	Agonistes de protéine kinase c
US11766447B2 (en)	2019-03-07	2023-09-26	Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.	3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
KR102808642B1 (ko)	2019-03-07	2025-05-14	인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이.	3'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭
KR102707808B1 (ko)	2019-03-07	2024-09-19	인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이.	2'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭
HUE059677T2 (hu)	2019-03-22	2022-12-28	Gilead Sciences Inc	Áthidalt triciklusos karbamoilpiridon-vegyületek és ezek gyógyszerészeti alkalmazása
TWI751517B (zh)	2019-04-17	2022-01-01	美商基利科學股份有限公司	類鐸受體調節劑之固體形式
TW202210480A (zh)	2019-04-17	2022-03-16	美商基利科學股份有限公司	類鐸受體調節劑之固體形式
TW202104210A (zh)	2019-04-17	2021-02-01	美商基利科學股份有限公司	Hiv蛋白酶抑制劑
WO2020214647A1 (fr)	2019-04-17	2020-10-22	Gilead Sciences, Inc.	Formes solides d'un inhibiteur de protéase du vih
TW202231277A (zh)	2019-05-21	2022-08-16	美商基利科學股份有限公司	鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
EP3972695A1 (fr)	2019-05-23	2022-03-30	Gilead Sciences, Inc.	Exo-méthylène-oxindoles substitués qui sont des inhibiteurs de hpk1/map4k1
RU2717101C1 (ru)	2019-06-03	2020-03-18	Андрей Александрович Иващенко	Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
US20220305115A1 (en)	2019-06-18	2022-09-29	Janssen Sciences Ireland Unlimited Company	Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
AU2020301161B2 (en)	2019-06-25	2023-10-26	Gilead Sciences, Inc.	FLT3L-Fc fusion proteins and methods of use
CA3145791A1 (fr)	2019-07-16	2021-01-21	Gilead Sciences, Inc.	Vaccins contre le vih et leurs procedes de fabrication et d'utilisation
US20220257619A1 (en)	2019-07-18	2022-08-18	Gilead Sciences, Inc.	Long-acting formulations of tenofovir alafenamide
US20220296619A1 (en)	2019-08-19	2022-09-22	Gilead Sciences, Inc.	Pharmaceutical formulations of tenofovir alafenamide
WO2021108544A1 (fr)	2019-11-26	2021-06-03	Gilead Sciences, Inc.	Inhibiteurs de capside pour la prévention du vih
ES3001984T3 (en)	2019-12-24	2025-03-06	Carna Biosciences Inc	Diacylglycerol kinase modulating compounds
EP4110783A1 (fr)	2020-02-24	2023-01-04	Gilead Sciences, Inc.	Composés tétracycliques pour le traitement d'une infection par le vih
AU2021237718B2 (en)	2020-03-20	2023-09-21	Gilead Sciences, Inc.	Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
WO2021236944A1 (fr)	2020-05-21	2021-11-25	Gilead Sciences, Inc.	Compositions pharmaceutiques contenant du bictégravir
TWI858267B (zh)	2020-06-25	2024-10-11	美商基利科學股份有限公司	用於治療hiv之蛋白殼抑制劑
CN116194144A (zh)	2020-08-07	2023-05-30	吉利德科学公司	膦酰胺核苷酸类似物的前药及其药物用途
CA3192145A1 (fr)	2020-09-30	2022-04-07	Gilead Sciences, Inc.	Composes de carbamoylpyridone tricyclique pontes et leurs utilisations
TW202406932A (zh)	2020-10-22	2024-02-16	美商基利科學股份有限公司	介白素2-Fc融合蛋白及使用方法
US20220144923A1 (en)	2020-11-11	2022-05-12	Gilead Sciences, Inc.	METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES
PE20231297A1 (es)	2021-01-19	2023-08-22	Gilead Sciences Inc	Compuestos de piridotriazina sustituidos y usos de estos
US20220389394A1 (en)	2021-05-18	2022-12-08	Gilead Sciences, Inc.	METHODS OF USING FLT3L-Fc FUSION PROTEINS
JP7654118B2 (ja)	2021-06-23	2025-03-31	ギリアードサイエンシーズ，インコーポレイテッド	ジアシルグリセロールキナーゼ調節化合物
JP7651018B2 (ja)	2021-06-23	2025-03-25	ギリアードサイエンシーズ，インコーポレイテッド	ジアシルグリセロールキナーゼ調節化合物
AU2022297367B2 (en)	2021-06-23	2025-04-10	Gilead Sciences, Inc.	Diacylglyercol kinase modulating compounds
WO2022271677A1 (fr)	2021-06-23	2022-12-29	Gilead Sciences, Inc.	Composés de modulation de la diacylglycérol kinase
TW202342447A (zh)	2021-12-03	2023-11-01	美商基利科學股份有限公司	用於ｈｉｖ病毒感染之治療性化合物
TW202412779A (zh)	2021-12-03	2024-04-01	美商基利科學股份有限公司	用於hiv病毒感染之治療性化合物
JP7765637B2 (ja)	2021-12-03	2025-11-06	ギリアードサイエンシーズ，インコーポレイテッド	Ｈｉｖウイルス感染症のための治療化合物
TW202446773A (zh)	2022-04-06	2024-12-01	美商基利科學股份有限公司	橋聯三環胺甲醯基吡啶酮化合物及其用途
US20240034724A1 (en)	2022-07-01	2024-02-01	Gilead Sciences, Inc.	Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
AU2023307100A1 (en)	2022-07-12	2025-01-02	Gilead Sciences, Inc.	Hiv immunogenic polypeptides and vaccines and uses thereof
CN119768183A (zh)	2022-08-26	2025-04-04	吉利德科学公司	用于广泛中和抗体的给药和安排方案
EP4598934A1 (fr)	2022-10-04	2025-08-13	Gilead Sciences, Inc.	Analogues de 4'-thionucléosides et leur utilisation pharmaceutique
US20240390349A1 (en)	2023-04-19	2024-11-28	Gilead Sciences, Inc.	Dosing regimen of capsid inhibitor
WO2024249517A1 (fr)	2023-05-31	2024-12-05	Gilead Sciences, Inc.	Composés anti-vih
AU2024281548A1 (en)	2023-05-31	2025-11-13	Gilead Sciences, Inc.	Solid forms of compounds useful in the treatment of hiv
US20250042926A1 (en)	2023-05-31	2025-02-06	Gilead Sciences, Inc.	Therapeutic compounds for hiv
WO2025029247A1 (fr)	2023-07-28	2025-02-06	Gilead Sciences, Inc.	Régime hebdomadaire de lénacapavir pour le traitement et la prévention du vih
WO2025042394A1 (fr)	2023-08-23	2025-02-27	Gilead Sciences, Inc.	Schéma posologique d'un inhibiteur de capside du vih
WO2025076542A1 (fr)	2023-10-05	2025-04-10	Jones R Brad	Atovaquone comme inducteur de ros destiné à être utilisé dans l'élimination de lymphocytes t infectés par le vih
US20250127801A1 (en)	2023-10-11	2025-04-24	Gilead Sciences, Inc.	Bridged tricyclic carbamoylpyridone compounds and uses thereof
TW202515549A (zh)	2023-10-11	2025-04-16	美商基利科學股份有限公司	橋聯三環胺甲醯基吡啶酮化合物及其用途
TW202530227A (zh)	2023-10-11	2025-08-01	美商基利科學股份有限公司	橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2025137245A1 (fr)	2023-12-22	2025-06-26	Gilead Sciences, Inc.	Formes solides d'inhibiteurs de l'intégrase du vih
US20250296932A1 (en)	2024-03-01	2025-09-25	Gilead Sciences, Inc.	Pharmaceutical compositions comprising hiv integrase inhibitors
US20250289822A1 (en)	2024-03-01	2025-09-18	Gilead Sciences, Inc.	Solid forms of hiv integrase inhibitors
US20250333424A1 (en)	2024-03-01	2025-10-30	Gilead Sciences, Inc.	Antiviral compounds
WO2025212814A1 (fr)	2024-04-03	2025-10-09	Gilead Sciences, Inc.	Composés anti-vih

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6463518A (en)	1987-09-02	1989-03-09	Otsuka Pharma Co Ltd	Antiarrhythmic agent
WO1989007939A2 (fr)	1988-03-01	1989-09-08	The Upjohn Company	Coumarines permettant d'inhiber la transcriptase inverse chez les etres humains
JPH03227923A (ja)	1990-01-30	1991-10-08	Sawai Seiyaku Kk	ひと免疫不全ウイルス疾患処置剤
GB9005518D0 (en)	1990-03-12	1990-05-09	Wellcome Found	Heterocyclic compounds
AU2436792A (en) *	1991-08-16	1993-03-16	Merck & Co., Inc.	Quinazoline derivatives as inhibitors of hiv reverse transcriptase
DE4208304A1 (de)	1992-03-16	1993-09-23	Merck Patent Gmbh	2-oxochinolinderivate
NO179904C (no)	1992-09-04	1997-01-08	Takeda Chemical Industries Ltd	Kondenserte heterocykliske forbindelser og deres anvendelse
IL108459A0 (en)	1993-02-05	1994-04-12	Opjohn Company	4-Hydroxy-benzopyran-2-ones and 4-hydroxy-cycloalkyl [B] pyran-2-ones useful for treating infections due to hiv and other retroviruses
DE19528418A1 (de)	1995-08-02	1997-02-06	Merck Patent Gmbh	Endothelin-Rezeptor-Antagonisten
US6069151A (en)	1996-11-06	2000-05-30	Darwin Discovery, Ltd.	Quinolines and their therapeutic use
US6018049A (en)	1996-12-26	2000-01-25	Shionogi & Co., Ltd.	Process for the preparation of carbamoylated imidazole derivatives
FR2761687B1 (fr) *	1997-04-08	2000-09-15	Centre Nat Rech Scient	Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques
FR2772761B1 (fr)	1997-12-23	2000-05-26	Lipha	Nouveaux derives de n-phenylamide et n-pyridylamide, leur procede de preparation et compositions pharmaceutiques les contenant
US6395916B1 (en)	1998-07-10	2002-05-28	Massachusetts Institute Of Technology	Ligands for metals and improved metal-catalyzed processes based thereon
US6307087B1 (en)	1998-07-10	2001-10-23	Massachusetts Institute Of Technology	Ligands for metals and improved metal-catalyzed processes based thereon
ES2281975T3 (es)	1998-12-04	2007-10-01	Bristol-Myers Squibb Company	Derivados 3-sustituidos de 4-arilquinolin-2-ona como moduladores de los canales de potasio.
AU2001234690A1 (en)	2000-02-01	2001-08-14	Cor Therapeutics, Inc.	2-(1h)-quinolone and 2-(1h)-quinoxalone inhibitors of factor xa
FR2819507B1 (fr) *	2001-01-17	2007-09-28	Inst Rech Developpement Ird	Quinoleines substituees pour le traitement de co-infections a protozoaires et a retrovirus
ATE387428T1 (de)	2001-05-21	2008-03-15	Hoffmann La Roche	Chinolinderivate als liganden für den neuropeptid-y-rezeptor
US20030109509A1 (en)	2001-10-11	2003-06-12	Alcon, Inc.	Methods for treating dry eye
DE10155076A1 (de)	2001-11-09	2003-05-22	Merck Patent Gmbh	Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen
FR2839646B1 (fr) *	2002-05-17	2008-04-11	Bioalliance Pharma	Utilisation de derives de quinoleine a effet anti-integrase et ses applications
EP1541558B1 (fr) *	2002-08-13	2008-08-13	Shionogi & Co., Ltd.	Composes heterocycliques a activite inhibitrice de l'integrase du vih
PE20040840A1 (es)	2002-11-20	2004-12-30	Japan Tobacco Inc	Derivados de 4-oxoquinolina como inhibidores de la integrasa del vih
US7642277B2 (en)	2002-12-04	2010-01-05	Boehringer Ingelheim International Gmbh	Non-nucleoside reverse transcriptase inhibitors
AU2004298486A1 (en)	2003-12-12	2005-06-30	Wyeth	Quinolines useful in treating cardiovascular disease
US20060094755A1 (en) *	2004-10-28	2006-05-04	Bioflexis, Llc	Novel quinoline-based metal chelators as antiviral agents
AU2006228278C1 (en)	2005-03-31	2011-06-23	Msd Italia S.R.L.	HIV integrase inhibitors
LT3372281T (lt)	2005-04-28	2021-12-10	Viiv Healthcare Company	Policiklinis karbamoilpiridono darinys, turintis živ integrazės inhibitorinį aktyvumą
US20080280849A1 (en)	2005-06-01	2008-11-13	Herve Leh	Synergic Combinations Comprising a Quinoline Compound and Other Hiv Infection Therapeutic Agents
WO2007039218A1 (fr)	2005-10-04	2007-04-12	Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa	Inhibiteurs de l’intégrase du vih
BRPI0617842A2 (pt)	2005-10-27	2011-08-09	Shionogi & Co	composto ou um sal farmaceuticamente aceitável ou um solvato do mesmo, e, composição farmacêutica
US7939545B2 (en) *	2006-05-16	2011-05-10	Boehringer Ingelheim International Gmbh	Inhibitors of human immunodeficiency virus replication
JP5269086B2 (ja)	2007-11-15	2013-08-21	ギリアードサイエンシスインコーポレーテッド	ヒト免疫不全ウイルスの複製阻害薬
EA201200631A1 (ru)	2007-11-16	2012-11-30	Джилид Сайенсиз, Инк.	Ингибиторы репликации вируса иммунодефицита человека
JP2014510139A (ja)	2011-04-04	2014-04-24	ギリアードサイエンシーズ，インコーポレイテッド	固体形態のｈｉｖ阻害剤
CA2830838A1 (fr)	2011-04-04	2012-11-10	Gilead Sciences, Inc.	Procede de preparation d'un inhibiteur de l'integrase du vih

2008
- 2008-09-11 EA EA201200631A patent/EA201200631A1/ru unknown
- 2008-09-11 UA UAA201007141 patent/UA100250C2/uk unknown
- 2008-09-11 SG SG2012083531A patent/SG185995A1/en unknown
- 2008-09-11 US US12/742,997 patent/US8354429B2/en active Active
- 2008-09-11 EP EP13197322.4A patent/EP2757096A1/fr not_active Withdrawn
- 2008-09-11 JP JP2010533392A patent/JP5285709B2/ja active Active
- 2008-09-11 BR BRPI0820307A patent/BRPI0820307A2/pt not_active IP Right Cessation
- 2008-09-11 MX MX2010005334A patent/MX2010005334A/es active IP Right Grant
- 2008-09-11 EP EP08800314.0A patent/EP2220046B1/fr active Active
- 2008-09-11 NZ NZ585226A patent/NZ585226A/xx not_active IP Right Cessation
- 2008-09-11 AU AU2008323558A patent/AU2008323558C1/en not_active Ceased
- 2008-09-11 CN CN2008801247428A patent/CN101918365B/zh not_active Expired - Fee Related
- 2008-09-11 CA CA2707418A patent/CA2707418C/fr not_active Expired - Fee Related
- 2008-09-11 EA EA201000777A patent/EA019259B1/ru not_active IP Right Cessation
- 2008-09-11 WO PCT/CA2008/001611 patent/WO2009062285A1/fr not_active Ceased
- 2008-09-11 KR KR1020107013072A patent/KR20100097156A/ko not_active Ceased
- 2008-11-14 UY UY31472A patent/UY31472A1/es not_active Application Discontinuation
- 2008-11-14 TW TW097144269A patent/TWI437992B/zh not_active IP Right Cessation
- 2008-11-14 PE PE2008001933A patent/PE20091000A1/es not_active Application Discontinuation
- 2008-11-14 PE PE2012001160A patent/PE20130008A1/es not_active Application Discontinuation
- 2008-11-14 CL CL2008003406A patent/CL2008003406A1/es unknown
- 2008-11-14 PE PE2012001161A patent/PE20130009A1/es not_active Application Discontinuation
- 2008-11-14 AR ARP080104990A patent/AR069335A1/es not_active Application Discontinuation
2010
- 2010-05-06 IL IL205581A patent/IL205581A/en not_active IP Right Cessation
- 2010-05-10 ZA ZA2010/03283A patent/ZA201003283B/en unknown
- 2010-05-14 TN TN2010000212A patent/TN2010000212A1/fr unknown
- 2010-05-14 CO CO10058231A patent/CO6280400A2/es active IP Right Grant
- 2010-05-27 EC EC2010010206A patent/ECSP10010206A/es unknown
- 2010-06-09 MA MA32901A patent/MA31906B1/fr unknown
2012
- 2012-11-21 US US13/683,761 patent/US8710230B2/en active Active
2013
- 2013-05-31 JP JP2013115884A patent/JP2013241410A/ja not_active Withdrawn
2014
- 2014-02-28 US US14/194,520 patent/US20140296228A1/en not_active Abandoned
2015
- 2015-01-08 HK HK15100191.0A patent/HK1199731A1/en unknown

Also Published As

Publication number	Publication date
CO6280400A2 (es)	2011-05-20
TWI437992B (zh)	2014-05-21
UA100250C2 (uk)	2012-12-10
ECSP10010206A (es)	2010-06-29
NZ585226A (en)	2012-08-31
AU2008323558C1 (en)	2014-05-01
US8710230B2 (en)	2014-04-29
EA201200631A1 (ru)	2012-11-30
EA201000777A1 (ru)	2010-12-30
EP2220046A4 (fr)	2011-01-05
IL205581A0 (en)	2010-11-30
PE20130009A1 (es)	2013-02-05
CA2707418C (fr)	2013-11-19
SG185995A1 (en)	2012-12-28
MX2010005334A (es)	2010-05-27
US20140296228A1 (en)	2014-10-02
CN101918365B (zh)	2013-10-09
CL2008003406A1 (es)	2010-01-11
WO2009062285A1 (fr)	2009-05-22
EP2220046B1 (fr)	2014-06-18
HK1199731A1 (en)	2015-07-17
HK1147096A1 (en)	2011-07-29
EP2757096A9 (fr)	2014-11-26
JP2013241410A (ja)	2013-12-05
EP2220046A1 (fr)	2010-08-25
JP5285709B2 (ja)	2013-09-11
US20100311735A1 (en)	2010-12-09
IL205581A (en)	2014-06-30
CA2707418A1 (fr)	2009-05-22
EA019259B1 (ru)	2014-02-28
UY31472A1 (es)	2009-07-17
US8354429B2 (en)	2013-01-15
AU2008323558B2 (en)	2013-10-17
PE20091000A1 (es)	2009-08-14
KR20100097156A (ko)	2010-09-02
PE20130008A1 (es)	2013-02-05
ZA201003283B (en)	2011-03-30
AU2008323558A1 (en)	2009-05-22
US20130197231A1 (en)	2013-08-01
AR069335A1 (es)	2010-01-13
EP2757096A1 (fr)	2014-07-23
JP2011503116A (ja)	2011-01-27
CN101918365A (zh)	2010-12-15
TW200932227A (en)	2009-08-01
BRPI0820307A2 (pt)	2019-09-24
MA31906B1 (fr)	2010-12-01

Publication	Publication Date	Title
TN2010000212A1 (en)	2011-11-11	Inhibitors of human immunodeficiency virus replication
EA201101620A1 (ru)	2012-05-30	Ингибиторы репликации вируса иммунодефицита человека
UY30350A1 (es)	2008-01-02	Inhibidores de la replicacion del virus de la inmunodeficiencia humana
UA104885C2 (uk)	2014-03-25	Ізотіазолілоксифеніламідини та їх застосування як фунгіцидів
MY151986A (en)	2014-07-31	Adamantyl diamide derivatives and uses of same
MX2009013349A (es)	2010-01-20	Compuestos quimicos.
EA200870193A1 (ru)	2009-02-27	Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
GEP20146125B (en)	2014-07-25	Aminopyrimidines as syk inhibitors
GEP20186838B (en)	2018-04-10	5-phenoxy-3h-pyrimidin-4-one derivatives and their usage as hiv reverse transcriptase inhibitors
BRPI0917017B8 (pt)	2021-05-25	inibidores de pirrol de s-nitrosoglutationa redutase como agentes terapêuticos
EA201101397A1 (ru)	2012-05-30	Ингибиторы репликации вируса иммунодефицита человека
UY30881A1 (es)	2008-09-02	Derivados de fenotiazina, procedimientos y su uso como productos farmacéuticos
IN2012DN00869A (fr)	2015-07-10
GEP20156368B (en)	2015-09-25	Non-nucleoside reverse transcriptase inhibitors
MX2012003644A (es)	2012-04-30	Compuestos de 2-piridona empleados como inhibidores de la elastasa neutrofila.
MX2011011733A (es)	2012-02-01	Inhiibidores de dihidroorotato deshidrogenasa como compuestos virostaticos.
MX2012006805A (es)	2012-07-10	Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa.
CR11423A (es)	2010-06-28	NUEVOS INHIBIDORES DE sEH Y SU USO
UA102858C2 (ru)	2013-08-27	Производные пиридино-пиридинонов, способ их получения и применения в терапии
WO2011143772A9 (fr)	2012-12-20	Inhibiteurs de la réplication du vih
MX2009012222A (es)	2009-12-01	Dihidroquinonas y dihidronaftiridinas como inhibidores de las quinasas c-jun-n-terminales.
JO2682B1 (en)	2013-03-03	Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
MA32723B1 (fr)	2011-10-02	Derives d'anilino-pyrimidine a substitution sulfoximine en tant qu'inhibiteurs de cdk, leur preparation et leur utilisation comme medicaments
MX343505B (es)	2016-11-04	Metodos y composiciones para inhibir la transmision del vih.
EA201290229A1 (ru)	2012-08-30	Производные спиролактама и их применение